Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online December 1, 2022.
Article Versions
- You are currently viewing a Latest version of this article (December 1, 2022 - 04:00).
- latest version (January 15, 2023 - 04:02).
- View the most recent version of this article
Copyright & Usage
© 2022 The Journal of Rheumatology
Author Information
- Lykke Midtbøll Ørnbjerg,
- Kathrine Rugbjerg,
- Stylianos Georgiadis,
- Simon Horskjær,
- Lykke Midtbøll Ørnbjerg,
- Kathrine Rugbjerg,
- Stylianos Georgiadis,
- Simon Horskjær Rasmussen,
- Ulf Lindström,
- Karel Pavelka,
- Neslihan Yilmaz,
- Ennio Giulio Favalli,
- Michael J. Nissen,
- Brigitte Michelsen,
- Elsa Vieira-Sousa,
- Gareth T. Jones,
- Ruxandra Ionescu,
- Heikki Relas,
- Carlos Sanchez-Piedra,
- Matija Tomšič,
- Arni Jon Geirsson,
- Irene van der Horst-Bruinsma,
- Johan Askling,
- Anne Gitte Loft,
- Lucie Nekvindova,
- Haner Direskeneli,
- Florenzo Iannone,
- Karen Minde Fagerli,
- Maria José Santos,
- Gary J. Macfarlane,
- Catalin Codreanu,
- Kari Eklund,
- Manuel Pombo-Suarez,
- Ziga Rotar,
- Bjorn Gudbjornsson,
- Tamara Rusman,
- Mikkel Østergaard and
- Merete Lund Hetland
- FUNDING: The EuroSpA Research Collaboration Network was financially supported by Novartis Pharma AG. Novartis had no influence on the data collection, statistical analyses, manuscript preparation or decision to submit the manuscript.
COMPETING INTERESTS: KR: research grant paid to employer from Novartis; LMØ: research grant paid to employer from Novartis; SG: research grant paid to employer from Novartis; SHR: research grant paid to employer from Novartis; UL: none; KP: Roche, BMS, AbbVie, Celgene, Eli Lilly, MSD, Novartis, Pfizer, Roche, UCB, Egis, Medac, Biogen; NY: Consultation fees from Abbvie, Novartis, Pfizer, Johnson&Johnson; EGF: Speaker and consultation fees from Eli Lilly, MSD, Novartis and Janssen; MJN: Speaker fees: AbbVie, Eli Lilly, MSD, Novartis; BM: Novartis; EVS: Research grants: MSD, Pfizer, UCB and speaker fees: Novartis, Abbvie, MSD, Celgene, UCB; GTJ: Abbvie, Pfizer, UCB, Amgen (Celgene), GSK; RI: Speaker fees: Abbvie, Boehringer- Ingelheim, BMS, Novartis, Sandoz, Pfizer, Eli Lilly, Zentiva; HR: Congress fees, speaker fees from Abbvie, Celgene, Pfizer; CSP: none; MT: AbbVie, Amgen, Biogen, Eli Lilly, Janssen, Medias, Medis, MSD, Novartis, OPH Oktal Pharma, Sandoz and Pfizer; AJG: none; IH: AbbVie, Lilly, Novartis , UCB, BMS, MSD, UCB, Pfizer; JA: PI for agreements between Abbvie, Astra-Zeneca, BMS, Eli Lilly, MSD, Pfizer, Roche, Samsung Bioepis, Sanofi, and UCB, for ARTIS safety monitoring; AGL: AbbVie, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, UCB; LN: none; HD: Research Grants, Educational travel support, Speaker and Consulting Fees from Abbvie, Pfizer, Roche, MSD, UCB, Amgen, Novartis, BMS, Celgene and Abdi-ıbrahim; FI: Speaker/consultation fees from AbbVie, Roche, MSD, UCB, Lilly, Janssen, Sanofi, Pfizer, Novartis; AC: Consulting and/or speaking fees from Abbvie, Eli-Lilly, MSD, Novartis, Pfizer; KMF: none; MJS: Speaker fees from Abbvie, Pfizer and Novartis; GJM: Research grant from GSK; CC: Speaker and consulting fees from AbbVie, Amgen, Egis, Ewopharma, Lilly, Novartis, Pfizer, Roche, Sandoz, UCB; KE: Consulting fees: Amgen, Celgene, Gilag, Gilead, Janssen, Lilly, Novartis, Pfizer, Roche, Sobi, UCB; MP: Consulting fees from Abbvie, MSD, Roche; ZR: Speaker and consultation fees from Abbvie, Amgen, Boehringer-Ingelheim, Celgene, Eli Lilly, MSD, Novartis, Pfizer, Roche, Sandoz, Sanofi, UCB; BG: Speaker fees from Novartis and Amgen; TR: none; MØ: research grants from Abbvie, BMS, Merck, Celgene and Novartis, and speaker and/or consultancy fees from Abbvie, BMS, Boehringer-Ingelheim, Celgene, Eli-Lilly, Hospira, Janssen, Merck, Novartis, Novo, Orion, Pfizer, Regeneron, Roche, Sandoz, Sanofi and UCB; MLH: Research grants from Abbvie, Biogen, BMS, Celltrion, Eli Lilly, Janssen Biologics B.V, Lundbeck Foundation, MSD, Pfizer, Roche, Samsung Biopies, Sandoz, Novartis.
STATEMENT OF ETICS AND CONSENT: All participating registries obtained the necessary approvals in accordance with legal, compliance and regulatory requirements from national Data Protection Agencies and/or Research Ethics Boards prior to the data transfer to the EuroSpA coordinating center.
CORRESPONDING AUTHOR: Lykke Midtbøll Ørnbjerg, COPECARE, Rigshospitalet, Valdemar Hansens Vej 17, 2600 Glostrup, Denmark. Email: lykke.midtboell.oernbjerg@regionh.dk